Seven Grand Managers LLC Invests $2.65 Million in Kestra Medical Technologies, Ltd. $KMTS

Seven Grand Managers LLC bought a new position in shares of Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 100,000 shares of the company’s stock, valued at approximately $2,652,000.

A number of other large investors also recently made changes to their positions in the company. Alliancebernstein L.P. increased its stake in shares of Kestra Medical Technologies by 13.7% during the third quarter. Alliancebernstein L.P. now owns 1,491,970 shares of the company’s stock worth $35,449,000 after purchasing an additional 179,885 shares during the period. Millennium Management LLC bought a new position in shares of Kestra Medical Technologies during the first quarter worth approximately $11,036,000. Geode Capital Management LLC increased its stake in shares of Kestra Medical Technologies by 26.5% during the fourth quarter. Geode Capital Management LLC now owns 419,115 shares of the company’s stock worth $11,117,000 after purchasing an additional 87,753 shares during the period. UBS Group AG grew its position in Kestra Medical Technologies by 34.9% during the fourth quarter. UBS Group AG now owns 270,058 shares of the company’s stock worth $7,162,000 after buying an additional 69,908 shares in the last quarter. Finally, Jennison Associates LLC grew its position in Kestra Medical Technologies by 15.0% during the fourth quarter. Jennison Associates LLC now owns 219,355 shares of the company’s stock worth $5,817,000 after buying an additional 28,573 shares in the last quarter.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on KMTS shares. BTIG Research reissued a “buy” rating and set a $32.00 price target on shares of Kestra Medical Technologies in a research report on Tuesday, April 7th. Weiss Ratings reissued a “sell (d-)” rating on shares of Kestra Medical Technologies in a research report on Monday, March 23rd. Finally, The Goldman Sachs Group reduced their price target on Kestra Medical Technologies from $22.00 to $17.00 and set a “neutral” rating on the stock in a research report on Thursday, April 9th. Three investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $27.40.

Insider Buying and Selling at Kestra Medical Technologies

In other Kestra Medical Technologies news, insider Brian Daniel Webster sold 15,000 shares of the firm’s stock in a transaction on Friday, May 15th. The stock was sold at an average price of $20.96, for a total value of $314,400.00. Following the sale, the insider owned 334,786 shares of the company’s stock, valued at approximately $7,017,114.56. This trade represents a 4.29% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Over the last 90 days, insiders sold 45,000 shares of company stock valued at $919,050. Company insiders own 3.60% of the company’s stock.

Kestra Medical Technologies Trading Down 3.8%

Shares of NASDAQ:KMTS opened at $21.00 on Thursday. The company has a market capitalization of $1.23 billion, a P/E ratio of -5.30 and a beta of 0.82. Kestra Medical Technologies, Ltd. has a 1 year low of $13.25 and a 1 year high of $30.00. The company has a debt-to-equity ratio of 0.15, a current ratio of 7.32 and a quick ratio of 7.32. The business’s 50 day simple moving average is $20.65 and its 200 day simple moving average is $23.58.

Kestra Medical Technologies (NASDAQ:KMTS) last issued its earnings results on Tuesday, March 17th. The company reported ($0.61) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.01). The business had revenue of $24.55 million during the quarter. Kestra Medical Technologies had a negative net margin of 171.87% and a negative return on equity of 65.49%. The business’s quarterly revenue was up 62.7% on a year-over-year basis. On average, research analysts anticipate that Kestra Medical Technologies, Ltd. will post -2.34 EPS for the current fiscal year.

Kestra Medical Technologies Profile

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.